rs116144992 - MTARC2P1 - GRM7-AS3
Magnitude 2.2 · 1 study on file
Reported associations
-
Genome-wide association study of paliperidone efficacy - Unknown journal (n.d.) · Unknown authors · PubMed 27846195
ABSTRACT: Supplemental Digital Content is available in the text. Objective Clinical response to the atypical antipsychotic paliperidone is known to vary among schizophrenic patients. We carried out a genome-wide association study to identify common genetic variants predictive of paliperidone efficacy. Methods We leveraged a collection of 1390 samples from individuals of European ancestry enrolled in 12 clinical studies investigating the efficacy of the extended-release tablet paliperidone ER (n1=490) and the once-monthly injection paliperidone palmitate (n2=550 and n3=350). We carried out a genome-wide association study using a general linear model (GLM) analysis on three separate cohorts, followed by meta-analysis and using a mixed linear model analysis on all samples. The variations in r
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
rs116144992 and paliperidone response in schizophrenia Moderate
Genetic association identified in large schizophrenia treatment study showing variant-related variation in response to paliperidone antipsychotic
If you have schizophrenia or are considering paliperidone treatment, discuss this variant with your psychiatrist